Aktis Oncology (NASDAQ:AKTS) Hits New 52-Week High – Time to Buy?

Aktis Oncology (NASDAQ:AKTS)’s share price reached a new 52-week high on Thursday . The stock traded as high as $29.50 and last traded at $30.7050, with a volume of 828 shares changing hands. The stock had previously closed at $28.70.

Analysts Set New Price Targets

A number of research analysts have commented on AKTS shares. Weiss Ratings raised Aktis Oncology from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday. HC Wainwright upped their target price on Aktis Oncology from $33.00 to $35.00 and gave the company a “buy” rating in a report on Tuesday, June 2nd. William Blair assumed coverage on Aktis Oncology in a research note on Wednesday, April 29th. They issued an “outperform” rating for the company. Finally, Raymond James Financial started coverage on shares of Aktis Oncology in a report on Monday, June 15th. They issued a “strong-buy” rating and a $40.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $34.00.

Aktis Oncology Price Performance

The business’s 50-day simple moving average is $20.40.

Aktis Oncology (NASDAQ:AKTS) last released its quarterly earnings results on Monday, March 30th. The technology company reported ($18.17) earnings per share for the quarter. The firm had revenue of $1.87 million during the quarter. Analysts anticipate that Aktis Oncology will post -1.62 earnings per share for the current fiscal year.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.